Ann: Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells, page-140

Small Caps Article, google “Weekly review: dovish Federal Reserve not enough to inspire Aussie market”


PharmAust (ASX: PAA)Another drug development small cap with a promising candidate against COVID-19 is PharmAust, with its lead candidates monepantel and monepantel sulfone.

Melbourne’s Walter and Eliza Hall Institute of Medical Research used the drugs on human respiratory cells with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

The research found that when both drugs were used virus particle counts of SARS-CoV-2 were suppressed by between 90% and 95%.

PharmAust noted preliminary research, using both drugs, has now demonstrated reduced SARS-CoV-2 infectivity in two independent cell lines – one non-human primate kidney and one human lung.

“Further preliminary confirmation of the activities of monepantel and monepantel sulfone against SARS-CoV-2 in alternative, and especially human, cellular models is an encouraging step,” PharmAust chief scientific officer Dr Richard Mollard said.

“These data will fuel further development of the effects of monepantel administration upon SARS-CoV-2 for clinical application,” he added.

The company cautioned the preliminary results required repetition and robust verification prior to clinical stage studies.

Havenots

Not long now...